Compare NRG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRG | UTHR |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0B | 20.3B |
| IPO Year | 2000 | 1999 |
| Metric | NRG | UTHR |
|---|---|---|
| Price | $161.43 | $493.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | $188.86 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 1.7M | 411.6K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ 62.56 | 16.08 |
| EPS | 6.78 | ★ 26.38 |
| Revenue | ★ $29,779,000,000.00 | $3,128,400,000.00 |
| Revenue This Year | $7.41 | $13.64 |
| Revenue Next Year | $16.16 | $5.78 |
| P/E Ratio | $23.83 | ★ $18.73 |
| Revenue Growth | 5.91 | ★ 13.50 |
| 52 Week Low | $79.57 | $266.98 |
| 52 Week High | $180.54 | $496.73 |
| Indicator | NRG | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 65.89 |
| Support Level | $163.25 | $474.59 |
| Resistance Level | $171.57 | $489.99 |
| Average True Range (ATR) | 6.32 | 10.16 |
| MACD | -0.04 | -0.69 |
| Stochastic Oscillator | 18.02 | 91.64 |
NRG Energy is one of the largest retail energy providers in the US, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home-services customers. NRG also is one of the largest US independent power producers, with 13 gigawatts of coal, gas, and oil power generation capacity primarily in Texas. The LS Power asset acquisition will add 13 GW of gas-fired power plants mostly in the Eastern US. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.